衍生物棕甲基尼丁通过增强脂毒性和线粒体功能障碍来取消宫癌细胞存活率
Sangavi Eswaran1, Roshan Mascarenhas2,3, Shama Prasada Kabekkodu4
1Department of Cell and Molecular Biology, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Cell communication and signaling : CCS
|May 3, 2025
概括
在宫癌细胞中恢复双C2像Beta域 (DOC2B) 改变了细胞外囊代谢物,丰富了棕甲酸 (PC). PC 显示出强大的抗癌作用,抑制了生长和迁移,这表明了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
- 细胞生物学 细胞生物学
背景情况:
- 双C2类似域β (DOC2B) 作为宫癌 (CC) 的转移抑制剂.
- 这项研究研究了DOC2B表达对细胞外囊泡 (EV) 代谢学的影响及其与瘤抑制功能的相关性.
研究的目的:
- 确定子宫外DOC2B表达是否会诱导EVs的全球代谢变化.
- 为了将这些代谢变化与DOC2B.已知的瘤抑制特性相关联.
主要方法:
- 使用逆转录病毒方法,DOC2B在子宫癌细胞SiHa中被异位表达.
- 进行了EVs的全球代谢概况分析.
- 细胞毒性测试,细胞增殖,迁移,细胞亡和线粒体功能测试使用棕甲基尼丁 (PC) 进行.
主要成果:
- 异位DOC2B表达显著改变了EV代谢物概况,特别是丰富了棕甲基 (PC).
- PC对SiHa和HeLaCC细胞表现出显著的细胞毒性,减少了增殖,迁移和诱导亡.
- PC诱导了线粒体功能障碍,代谢重编程,并在CC细胞中增强了西斯的细胞毒性.
结论:
- DOC2B恢复改变了EV代谢,导致抗癌代谢物PC的丰富.
- PC 显示出显著的抗癌性质,并可以增强化疗的疗效.
- 无论是DOC2B恢复还是PC应用,都代表了宫癌的潜在新型治疗策略.
关键词:
宫癌是发生在宫癌的原因之一.DOC2B 编辑 编辑 编辑 编辑细胞外囊泡中的细胞外囊泡.脂肪毒性 脂肪毒性代谢学 代谢学 代谢学线粒体中的线粒体.棕甲基卡尼丁是一种棕甲基卡尼丁.有反应性氧物种的反应性氧物种.更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.6K
04:20Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
839
相关概念视频
01:46Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
02:34Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K